Absci Corporation filed a Form 8-K on November 12, 2026, announcing its financial results for the third quarter ended September 30, 2026, and releasing a corporate presentation with internal pipeline program updates.
Artisan Partners Asset Management Inc. and affiliated entities filed Amendment No. 7 to Schedule 13G with the SEC on November 12, 2026, reporting beneficial ownership of approximately 3.4% of Twist Bioscience Corporation common stock as of September 30, 2026.
Vor Biopharma Inc. filed a Current Report on Form 8-K on November 12, 2026, disclosing that on November 11, 2026, the company entered into an amended and restated license agreement with RemeGen Co., Ltd. that expands the existing telitacicept license to include a second …
Twist Bioscience Corporation filed a Form 8-K on November 12, 2026, announcing the release of its financial results for the quarter and fiscal year ended September 30, 2026.
Enovix Corporation filed a Form 8-K with the U.S. Securities and Exchange Commission on November 12, 2026, announcing the release of its financial results for the third fiscal quarter of 2026.
Intuitive Machines, Inc. filed a Form 8-K current report on November 12, 2026, disclosing the issuance of a press release announcing its financial results for the fiscal quarter ended September 30, 2026.
Capstone Holding Corp. filed a Form 8-K with the SEC on November 12, 2026, announcing the release of its financial and operating results for the quarter ended September 30, 2026, along with an accompanying investor presentation.
News Corporation filed a Form 8-K on November 12, 2026, reporting the submission of daily stock repurchase transaction disclosures to the Australian Securities Exchange as required under ASX rules, with the earliest event date of November 11, 2026.
Skye Bioscience, Inc. filed a current report on November 12, 2026, disclosing that on November 10, 2026, a jury returned a unanimous verdict in favor of the company on all claims following a retrial in the Wendy Cunning vs. Skye Bioscience, Inc. matter in …
Sagimet Biosciences Inc. filed a Current Report on Form 8-K on November 12, 2026, announcing its financial results for the quarter ended September 30, 2026, and furnishing an updated investor presentation under Regulation FD.